Akbari M., Hassan-Zadeh V. Hyperglycemia Affects the Expression of Inflammatory Genes in Peripheral Blood Mononuclear Cells of Patients with Type 2 Diabetes // Immunol. Investig. 2018. Vol. 47. P. 654-665. DOI: 10.1080/08820139.2018.1480031.
Arcidiacono B., Iiritano S., Nocera A., Possidente K., Nevolo M.T., Ventura V. et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms // Exp. Diabetes Res. 2012, Jun. 4. P. 12. DOI:
10.1155/2012/789174.
Basu A.K. DNA damage, mutagenesis and cancer // Int. J. Mol. Sci. 2018. Vol. 19. P. 970. DOI: 10.3390/ijms19040970.
Baxter R. IGF binding proteins in cancer: mechanistic and clinical insights // Nat. Rev. Cancer. 2014. Vol. 14, N 5. P. 329-341. DOI: 10.1038/
nrc3720.
Boyd D.B. Insulin and cancer // Integr. Cancer Ther. 2003. Vol. 2, N 4. P. 315-329. DOI: 10.1177/1534735403259152.
Chan C.L., Ho R.S., Shek T.W., Kwong A. Diabetic mastopathy // Breast J. 2013. Vol. 19. P. 533-538. DOI: 10.1111/tbj.12158.
Chen C., Freeman R., Voigt L.F., Fitzpatrick A., Plymate S.R., Weiss N.S. Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor Receptor // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15. P. 2461-2466. DOI: 10.1158/1055-9965.EPI-06-0541.
D'Orazi G., Rinaldo C., Soddu S. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer // J. Exp. Clin. Cancer Res. 2012. Vol. 31. P. 63. DOI: 10.1186/1756-9966-31-63.
Dabrowski M., Szymanska-Garbacz E., Miszczyszyn Z., Derezinski T., Czupryniak L. Risk factors for cancer development in type 2 diabetes: a retrospective case-control study // BMC Cancer. 2016. Vol. 16. P. 785. DOI: 10.1186/s12885-016-2836-6.